Niosomes and discomes for ocular delivery of Naltrexone hydrochloride (cas 16676-29-2): Morphological, rheological, spreading properties and photo-protective effects
-
Add time:09/10/2019 Source:sciencedirect.com
Naltrexone hydrochloride (NTX) is a promising treatment for corneal disorders linked to diabetes mellitus (diabetic keratopathy). However, NTX has a major stability problem due to autoxidation, which is likely to hinder its formulation as eye drops for treatment of diabetic keratopathy. In this study, in-house developed NTX non-ionic surfactant vesicles (niosomes and discomes) were evaluated for their spreading, rheological properties and their ability to impede the inevitable autoxidation of NTX in aqueous solutions. The measured contact angles and spreading coefficients for niosomes reflected significantly (P < 0.05) better wetting and spreading abilities than the aqueous vehicle. The prepared niosomes were significantly more viscous (P < 0.05) than the aqueous solution. The lipid content, size and composition of niosomes are the main factors affecting the viscosity of niosomal dispersions. Exposure of NTX solution to artificial daylight illumination (10,000 lux) can produce extensive degradation of NTX due to oxidation. The prepared formulations were able to significantly (P < 0.05) protect the encapsulated NTX from the photo-induced oxidation compared with free NTX solutions. The investigated niosomes lend themselves as a potential ocular delivery modality for NTX.
We also recommend Trading Suppliers and Manufacturers of Naltrexone hydrochloride (cas 16676-29-2). Pls Click Website Link as below: cas 16676-29-2 suppliers
Prev:Novel in situ gelling ocular films for the opioid growth factor-receptor antagonist-Naltrexone hydrochloride (cas 16676-29-2): Fabrication, mechanical properties, mucoadhesion, tolerability and stability studies
Next:Research ArticlesStructural characterization of anhydrous naloxone‐ and Naltrexone hydrochloride (cas 16676-29-2) by high resolution laboratory X‐ray powder diffraction and thermal analysis) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Design of controlled release inert matrices of Naltrexone hydrochloride (cas 16676-29-2) based on percolation concepts09/27/2019
- Sex differences in the effect of bupropion and naltrexone combination on alcohol drinking in mice09/26/2019
- Original articleSimultaneous determination of naltrexone and bupropion in their co-formulated tablet utilizing green chromatographic approach with application to human urine09/25/2019
- Research ArticlesStructural characterization of anhydrous naloxone‐ and Naltrexone hydrochloride (cas 16676-29-2) by high resolution laboratory X‐ray powder diffraction and thermal analysis09/24/2019
- Novel in situ gelling ocular films for the opioid growth factor-receptor antagonist-Naltrexone hydrochloride (cas 16676-29-2): Fabrication, mechanical properties, mucoadhesion, tolerability and stability studies09/09/2019
- Hydrogels for diabetic eyes: Naltrexone loading, release profiles and cornea penetration09/08/2019
- Pharmaceutics, Preformulation and Drug DeliveryDesign and Evaluation of Controlled-Release Niosomes and Discomes for Naltrexone hydrochloride (cas 16676-29-2) Ocular Delivery09/07/2019
- In-vivo study of Naltrexone hydrochloride (cas 16676-29-2) release from an in-situ forming PLGA-PEG-PLGA system in the rabbit09/06/2019
-
Health and Chemical more >


